Biswas et al. (2022) confirmed that targeting of the SA1009-ALDH-RA axis brings back the sensitivity and reduces the tumor metastatic rate in patients with brain relapse. Their studies proved that RA upregulation by ALDH takes place via upregulation of SA1009. Targeting any of these targets brings back the sensitivity to osimertinib in EGFR-mutated lung cancer patients. Lavudi et al. (2023) also proved that targeting of ALDH1A1-RA-Pol theta has a potential in sensitizing the BRCA-mutated ovarian cancer and improves the efficacy of PARPi and increases the overall patient survival. This evidence concerns the gene ALDH1A1 and neoplasm.